Health inequities arise when economic, social, and political systems create barriers such as bias, mistrust, and limited access, that impact optimal care for underserved populations. Effective pharmaceutical development programs must go beyond a one-size-fits-all approach by understanding intersectional drivers—race, geography, culture, income, and more—that uniquely shape health outcomes.
Unearth Neighborhood-Level Social Inequities
With RTI Rarity™, our proprietary analytics engine, we are uniquely positioned to support clinical trial diversity and equity by:
RTI Rarity™ ensures your programs align with new FDA diversity mandates for drug, device, and biologic trials:
RTI Health Solutions bridges equity and innovation across the pharmaceutical lifecycle.
| Phase | Health Equity Focus |
|---|---|
| Discovery & Preclinical | Incorporate SDoH variables to predict real-world variability in drug response |
| Trial Design | Use LSI data to improve site selection and represent meaningful diversity |
| Evidence Generation & Access | Model economic and cultural factors, refine value communication, and support HTA/submissions |
| Commercial Launch | Implement equity-based pricing and messaging to ensure inclusive access |
